Search
  • sholehja

01/08/20 KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17™ Bladder Cancer Recurrence Test...more

20 views0 comments

Recent Posts

See All

2/4/21 URO17 For Detecting Bladder Cancer

URO17 is a urine test for detecting bladder cancer in people with symptoms associated with malignancy, including blood in the urine (haematuria) or lower urinary tract symptoms. It is also indicated f